Searchable abstracts of presentations at key conferences in endocrinology

ea0052p15 | (1) | UKINETS2017

Platinum-etoposide chemotherapy for extra-pulmonary high grade neuroendocrine carcinoma (EP-G3-NEC): A survey of clinical practice

Lamarca Angela , Frizziero Melissa , Barriuso Jorge , McNamara Mairead G , Hubner Richard A , Valle Juan W

Introduction: Platinum-etoposide chemotherapy is a globally established chemotherapy combination for EP-G3-NEC. However, there are many different schedules for such chemotherapy, and the preferred one for EP-G3-NEC has not been established.Methods: An international survey was created, and completed by colleagues with an expertise in the field of neuroendocrine neoplasms. The aim was to explore which schedules of platinum-etoposide chemotherapy are used a...

ea0068p14 | Abstracts | UKINETS2019

Liver embolisation for patients diagnosed with neuroendocrine neoplasms: systematic review and meta-analysis of the literature

Kanabar Rahul , Barriuso Jorge , McNamara Mairead , Mansoor Was , Hubner Richard , Valle Juan , Lamarca Angela

Background: Liver embolisation is one of the treatment options available for patients diagnosed with neuro-endocrine neoplasms (NEN), especially in the presence of carcinoid syndrome. It is still uncertain whether the benefits of the various types of embolisation treatments truly outweigh the complications in NENs. This systematic review assesses the available data relating to liver embolisation in patients with NENs.Methods: Eligible studies (identified...

ea0031p48 | Clinical biochemistry | SFEBES2013

A comparison of serum chromogranin A measurement with 24 h urine and serum 5-hydroxyindole acetic acid measurement in patients with NETs

Monaghan Phillip , Adaway Joanne , Valle Juan , Hubner Richard , Trainer Peter , Darby Denise , Keevil Brian

Introduction: Chromogranin-A (CgA) is a 49 kDa protein of the granin/secretogranin family originating from dense-core secretory granules within cells of the diffuse endocrine system. CgA is currently the best available diagnostic biomarker for neuroendocrine tumours (NETs) with recent clinical guidelines advocating the measurement of CgA as part of the baseline biochemical profile in patients presenting with symptoms suspicious of a gastroenteropancreatic NET.<p class="abs...

ea0087oc3 | Oral Communications | UKINETS2022

Outcomes in patients with advanced well-differentiated gastroenteropancreatic neuroendocrine tumours receiving PRRT early versus later

Robinson Matthew D , Chander Amarjot , Westwood Tom , Manoharan Prakash , Mansoor Was , Lamarca Angela , A Hubner Richard , W Valle Juan , G McNamara Mairead

Background: Neuroendocrine tumours (NETs) are rare malignancies; over 60% of primary lesions arise in the gastrointestinal tract and pancreas. Despite several practice-changing clinical trials, uncertainty persists around the most efficacious treatment sequence in patients with advanced well-differentiated gastroenteropancreatic (GEP) NETs, particularly in relation to peptide receptor radionuclide therapy (PRRT). This study aimed to investigate the progression-free survival (P...

ea0068p6 | Abstracts | UKINETS2019

Hepatic arterial embolisation for patients diagnosed with neuroendocrine neoplasms: experience from a European Neuroendocrine Tumour Society centre of excellence

Nuttall Christina , Lamarca Angela , McNamara Mairead , Barriuso Jorge , Lawrance Jeremy , Mullan Damian , Mansoor Was , Valle Juan , Hubner Richard

Background: Hepatic arterial embolisation (HAE) is a recommended treatment option for patients with neuro-endocrine neoplasms (NENs) and liver metastasis. We aimed to describe outcomes after HAE for NENs at a single United Kingdom centre and investigate the influence of tumour characteristics.Methods: Retrospective analysis of sequential patients with NENs undergoing HAE at The Christie NHS Foundation Trust between 2004 and 2018. Primary end points were ...

ea0046p3 | (1) | UKINETS2016

Health-related quality of life (HRQoL), anxiety, depression and impulsivity in patients with advanced Gastroenteropancreatic Neuroendocrine Tumours (GEPNETs)

Lewis Alexandra , Wang Xin , Magdalani Laurice , Bashir Colsom , Mansoor Wasat , Hubner Richard A , Valle Juan W , McNamara Mairead G

Background: In patients with advanced GEPNETs, psychological symptoms may result due to potential disturbances in biogenic amines, particularly serotonin. This study compared HRQoL, anxiety, depression, and impulsivity in patients with and without carcinoid syndrome (CS) and correlated with serum 5-HIAA.Methods: Consecutive patients with advanced GEPNETs (with liver metastases) receiving treatment, with and without CS completed (single time-point) HRQoL ...

ea0046p9 | (1) | UKINETS2016

Whole-exome sequencing (WES) of samples from patients with advanced pancreatic neuroendocrine tumours (pNETs) with exceptional responses vs. poor responders to targeted therapies; a TransNET study

Barriuso Jorge , Lamarca Angela , McNamara Mairead , Burgis Timothy , Manoharan Prakash , Hayes Andrew , Mansoor Wasat , Hubner Richard , Valle Juan

Background: Despite encouraging advances in the systemic therapy options for patients with pNETs (sunitinib and everolimus), no predictive biomarkers have been established for these drugs. We aimed to identify distinctive genomic alterations associated with benefit from treatment in patients with pNETs, by comparing exceptional-responders (ER) to poor-responders (PO).Methods: Patients who achieved an objective radiological response (complete or partial) ...

ea0060p03 | (1) | UKINETS2018

Second primary malignancies (SPMs) in patients with non-pulmonary well-differentiated neuroendocrine tumours (wdNETs)

Dafnis Anna , Raja Haseem , Chakrabarty Bipasha , Lamarca Angela , Hubner Richard A , Mansoor Wasat , Valle Juan W , McNamara Mairead

Background: Neuroendocrine tumours (NETs) are often associated with SPMs. This study aimed to identify SPMs in patients with non-pulmonary wdNETs.Methods: Patients seen at The Christie with non-pulmonary wdNETs from 2003–2017 were included. After exclusion of patients with hereditary predispositions, notes were retrospectively reviewed for location, functionality, treatment and temporal relation to diagnosis.Results: Of 854 pa...

ea0052p21 | (1) | UKINETS2017

Carboplatin-etoposide chemotherapy for patients with advanced extra-pulmonary (EP) poorly differentiated (PD) neuroendocrine carcinoma (NEC); outcomes from a European Neuroendocrine Tumour Society Centre of Excellence

Frizziero Melissa , Lamarca Angela , Kordatou Zoe , Barriuso Jorge , Nuttall Christina , McNamara Mairead G. , Hubner Richard A. , Mansoor Wasat , Manoharan Prakash , Valle Juan W.

Introduction: Platinum-etoposide is considered standard-of-care first-line treatment for patients diagnosed with advanced EP-PD-NECs. The optimal platinum-etoposide schedule remains undefined; carboplatin is often substituted for cisplatin, although quality data is lacking.Methods: Electronic records of patients with advanced EP-PD-NEC treated with carboplatin-etoposide (06/09-02/17) were reviewed retrospectively, with aim to provide real-life efficacy/s...

ea0068p12 | Abstracts | UKINETS2019

Systemic chemotherapy for inoperable Goblet Cell Adenocarcinomas (GCAs)

Barriuso Jorge , Lamarca Angela , Martin Amy , Chakrabarty Bipasha , Clouston Hamish , Mullamitha Saifee , McNamara Mairead , Marti-Marti Francisca , Hubner Richard , Saunders Mark , O'Dwyer Sarah , Braun Michael , Valle Juan

Background: Appendiceal GCAs (previously known as Goblet Cell Carcinoids) are considered to have an unpredictable behaviour; even in node-negative patients, metastases mainly local to the adjacent peritoneum are seen. The systemic chemotherapy (scx) is often borrowed from colon cancer regimens. We designed a retrospective study with the aim of describing the use of scx in these rare malignancies in our institution.Methods: Data from all consecutive cases...